Menu Search
Equities

Vivani Medical Inc

U5P:BER

Vivani Medical Inc

Actions
  • Price (EUR)1.18
  • Today's Change0.01 / 0.85%
  • Shares traded--
  • 1 Year change+23.56%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:40 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Vivani Medical Inc's net income fell 84.69% from a loss of 13.89m to a larger loss of 25.65m despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-44.89%
Return on equity-86.10%
Return on investment-50.97%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Vivani Medical Inc fell by 24.45m. Cash Flow from Financing totalled 133.00k or -- of revenues. In addition the company used 23.70m for operations while cash used for investing totalled 887.00k.
Cash flow per share-0.4557
Price/Cash flow per share--
Book value per share0.4316
Tangible book value per share0.4316
More ▼

Balance sheet in USDView more

Vivani Medical Inc uses little or no debt in its capital structure.
Current ratio4.55
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.